View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Chinese Patent Granted for Biomarkers for Stem Cell Therapy

🕔12/3/2018 9:34:26 AM 1379

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the State Intellectual Property Office of China has granted the Company a patent for the use of biomarkers to monitor disease progression in a patient having mesenchymal cell therapy for inflammatory conditions.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders

🕔11/22/2018 2:06:22 PM 1622

Regeneus Ltd (ASX:RGS) provides the Company's Chairman Address to Shareholders.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation for AusBiotech 2018

🕔10/31/2018 4:26:22 PM 1504

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results for the Period Ended 30 September 2018

🕔10/24/2018 9:08:53 AM 1400

Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) European Patent Office Issues Notice of Intention to Grant European Patent

🕔10/18/2018 9:11:57 AM 1562

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.4M

🕔9/6/2018 9:18:09 AM 2795

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) FY18 Results and Business Update

🕔8/30/2018 2:32:07 PM 2237

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to provide an overview of its results for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Annual Report 2018

🕔8/30/2018 2:13:22 PM 2153

Your Directors present their report for Regeneus Ltd (ASX:RGS) and its controlled entities for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Clinical Trial Results for Cancer Vaccine

🕔7/30/2018 9:45:25 AM 2689

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of its cancer vaccine which met the primary endpoint of safety and tolerability. The study known as the ACTIVATE trial, is the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results

🕔7/25/2018 10:00:00 AM 2157

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2018.

Read Full Article
###

98,431 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 236) (Last 30 Days: 1250) (Since Published: 45764) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media